AngioJet Reduces Complications, Coronary Events Compared To Urokinase
This article was originally published in The Gray Sheet
Possis Medical's AngioJet LF140 rheolytic thrombectomy catheter can significantly reduce in-hospital major cardiac events, bleeding complications and vascular complications in patients with intracoronary thrombus as compared to intracoronary urokinase infusion, Stephen Ramee, MD, Ochsner Clinic, New Orleans, told attendees Nov. 9 at the American Heart Association's 71st annual Scientific Sessions in Dallas, Texas.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.